TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02909803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lentil Variety
Description: Participants will consume 8 varieties of lentils that are cooked by boiling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Bread
Description: Participants will consume white bread on at least two different test days
Study: NCT01522586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP09031
Description: DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
Study: NCT01872234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two-lead CRT-P
Description: The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
Study: NCT04498494

Intervention type: DEVICE
Intervention: ECG
Description: 12-lead ECG

Intervention type: DEVICE
Intervention: ECG
Description: 12-lead ECG
Study: NCT02385136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT02704910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Subthalamic stimulation
Description: Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Subthalamic stimulation
Description: Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
Study: NCT03810404

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate supplementation
Description: Interventions:~The experimental procedure for each athlete included an acute SB supplementation in a different-dose regimen in order to assess whether the dose affects the actual physical and exercise capacity (doses: 0.15-, 0.25-, 0.35- and 0.50 g/kgFFM (0.12-, 0.20-, 0.28- and 0.40 g/kgBM), respectively). SB (Alkala, SANUM, Poland) will be administered as dissolved form in a 750 ml of fluid (water + fruit juice). On testing days the SB will be taken before physical and exercise capacity tests session.~Between the SB and PLA or a PLA and SB treatments, a minimum 7-day washout period will be introduced.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Interventions:~The experimental procedure for each athlete will be included an PLA supplementation. Placebo will be administered in a form of 750 ml of fluid (water + fruit juice). On testing days the PLA will be taken before physical and exercise capacity tests session.~Between the PLA and SB or a SB and PLA treatments, a minimum 7-day washout period will be introduced.
Study: NCT04485429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 0.5 mg/kg every 12 hours intravenously for the first 14 days; followed by 0.5 mg/kg/day from day 15 to day 21; followed by 0.25mg/kg/day from day 22 to day 25; followed by 0.125 mg/kg/day, from day 26 to day 28 of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 0.5 mg/kg every 12 hours intravenously for the first 14 days; followed by 0.5 mg/kg/day from day 15 to day 21; followed by 0.25mg/kg/day from day 22 to day 25; followed by 0.125 mg/kg/day, from day 26 to day 28 of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.
Study: NCT00468039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin + metformin
Study: NCT03231982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group I
Description: Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group II
Description: Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
Study: NCT03455049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Andrographis Paniculata Ext
Description: Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Andrographis Paniculata Ext
Description: Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Andrographis Paniculata Ext
Description: Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
Study: NCT06526754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-Printed Liver Model
Description: Participants in the 3D Printed Model Group (3DP) will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. These models will be used to guide the surgical procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Simulation-Based Surgical Planning
Description: Participants in the 3D Virtual Model Group (3DV) will receive surgical planning based on digital simulations using the fastest AI-assisted segmentation method with manual adjustments from Phase Two. These digital simulations will be used to guide the surgical procedures.
Study: NCT03455049

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Andrographis Paniculata Ext
Description: Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
Study: NCT01616082

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Diet (LCD)
Description: A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Diet (LCD)
Description: A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Description: Individuals not on track to achieve their target weight by four weeks received the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects were given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~* Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~* Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated.
Study: NCT04350398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The horse is an excellent collaborator in situations of physical and mental disability, whether temporary or consolidated. It provides support to humans towards an impairment (anatomical or physiological), a disability, or a restriction of participation as defined by the WHO in 2001. Hippotherapy has a direct action on the sensorimotor capacities of the individual but also on their cognitive capacities, such as attention, memory, psychomotricity, emotions, perceptions, the sequencing of complex movements, or the experience of oneself and the functions of time. Overall, the strong demand from the sensitive, sensory and motor spheres promotes and interacts with the mechanisms linked to the execution of tasks in the cognitive domain (memory, attention, executive functions, speed of information processing, etc.) through the interactions of several neural networks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional therapy
Description: Personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
Study: NCT00186147

Intervention type: PROCEDURE
Intervention: collection and storage of tissue samples for research
Description: Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
Study: NCT00615433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: 120mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 15mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebor Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg tablets
Description: Lurasidone 40 mg tablets
Study: NCT02714634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate + targeted therapy administration
Description: * Methotrexate or leflunomide + adalimumab or~* Methotrexate or leflunomide + certolizumab or~* Methotrexate or leflunomide + etanercept or~* Methotrexate or leflunomide + golimumab or~* Methotrexate or leflunomide + infliximab or~* Methotrexate or leflunomide + abatacept or~* Methotrexate or leflunomide + rituximab or~* Methotrexate or leflunomide + tocilizumab or~* Methotrexate or leflunomide + sarilumab or~* Methotrexate or leflunomide + filgotinib or~* Methotrexate or leflunomide + upadacitinib or~* Methotrexate or leflunomide + Tofacitinib or~* Methotrexate or leflunomide + baricitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
Study: NCT00958529

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin Fiber Supplement
Description: Orange juice fortified with 0, 5g, and 10g of 2 inulin products
Study: NCT02688920

Intervention type: PROCEDURE
Intervention: EUS and OCT imaging
Description: Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography

Intervention type: PROCEDURE
Intervention: EUS and OCT imaging
Description: Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography
Study: NCT04488055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Line Facilitation (CLF)
Description: CLF is a motivational interviewing-based intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: In addition to receiving the brochure, EUC condition participants will meet with a therapist (in-person or remotely) for approximately 15 minutes for a descriptive overview of the brochure.
Study: NCT04250974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: acupuncture with electricity

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture
Description: acupuncture with electricity
Study: NCT05328232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: The parents of the babies included in the experimental group were asked to fill in the questionnaires. The infant's skin condition was assessed using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants. Each time the diaper was changed, the diaper area was cleaned with water and cotton wool and dried, 1-2 cc of natural extra virgin olive oil was applied, and the new diaper was fastened. At the end of each day, the diaper area was evaluated by the researcher and a nurse by using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants.
Study: NCT01663831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mosquito topical repellent
Description: Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
Study: NCT03849612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AID System
Description: AID system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
Study: NCT02603640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scanning
Study: NCT01623687

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Component for acetabulum (Regenerex RingLoc cup)
Description: A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Components for the acetabulum (Lubinus cross linked cup)
Description: cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroplasty components are for the femur (Cemented Lubinus SP II stem)
Description: Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
Study: NCT00937391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-6661)
Description: For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
Study: NCT04151342

Intervention type: DRUG
Intervention: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.
Description: Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.

Intervention type: DRUG
Intervention: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.
Description: Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.

Intervention type: OTHER
Intervention: Patient-reported outcomes (PROs)
Description: Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
Study: NCT02750215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib (INC280)
Description: treatment with Capmatinib (INC280)
Study: NCT00575250

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Osteoporosis Prevention and Self-Management Course
Description: Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Introductory education session on osteoporosis
Description: Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
Study: NCT04101201

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: µSmin® Plus
Description: µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
Study: NCT01990144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine+Rituximab
Description: Patients will receive :~* Rituximab 375 mg/m2 intravenously on day 1\*~* Bendamustine 90 mg/m2 intravenously on days 2 and 3\*\* Treatment will be administered on a 28-day cycle basis.~  * Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.~    * After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice.
Study: NCT01505647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live (AMP)
Description: One approximately 0.65-mL injection subcutaneously on Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zoster Vaccine, Live
Description: One approximately 0.65-mL injection subcutaneously on Day 1
Study: NCT04215133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise therapy
Description: inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise therapy
Description: inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.
Study: NCT02300727

Intervention type: DRUG
Group type: OTHER
Intervention: Curcumin-MTD
Description: 0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash-standard pharmacy preparation
Description: Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
Study: NCT03464695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2matic
Description: Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.
Study: NCT02859506

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory quotient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory quotient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory quotient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory quotient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olfactory liking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olfactory liking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory liking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olfactory liking
Study: NCT02691962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xen Matrix AB
Description: Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
Study: NCT04220853

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rhinomanometry in patients after septoplasty and/or turbinoplasty
Description: Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rhinomanometry in patients after septoplasty and/or turbinoplasty
Description: Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rhinomanometry in patients after septoplasty and/or turbinoplasty
Description: Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry in patients after septoplasty and/or turbinoplasty
Description: Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry in patients after septoplasty and/or turbinoplasty
Description: Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry in patients after septoplasty and/or turbinoplasty
Description: Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.